Biomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1A Data For TTX-MC138 In Advanced Solid Tumors

(MENAFN - Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) reported updated clinical data from its Phase 1a trial of TTX-MC138 in patients with relapsed or refractory, unresectable ...